At genome‐wide level, CLK inhibitors modulated a subset of AS events that are dysregulated across tumour types displaying CLK1 upregulation [89], suggesting their efficacy in reverting CLK‐mediated oncogenic features. This evidence concerns the gene CLK1 and neoplasm.